86 related articles for article (PubMed ID: 11027568)
1. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Biochem Biophys Res Commun; 2000 Oct; 276(3):909-16. PubMed ID: 11027568
[TBL] [Abstract][Full Text] [Related]
2. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Biochem Biophys Res Commun; 2001 Nov; 289(2):580-5. PubMed ID: 11716514
[TBL] [Abstract][Full Text] [Related]
3. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
4. Bivalent probes of the human multidrug transporter P-glycoprotein.
Pires MM; Hrycyna CA; Chmielewski J
Biochemistry; 2006 Sep; 45(38):11695-702. PubMed ID: 16981729
[TBL] [Abstract][Full Text] [Related]
5. P glycoprotein and the mechanism of multidrug resistance.
Váradi A; Szakács G; Bakos E; Sarkadi B
Novartis Found Symp; 2002; 243():54-65; discussion 65-8, 180-5. PubMed ID: 11990782
[TBL] [Abstract][Full Text] [Related]
6. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
[TBL] [Abstract][Full Text] [Related]
7. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
Zhu HJ; Wang JS; Markowitz JS; Donovan JL; Gibson BB; Gefroh HA; Devane CL
J Pharmacol Exp Ther; 2006 May; 317(2):850-7. PubMed ID: 16439618
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
Tang F; Ouyang H; Yang JZ; Borchardt RT
J Pharm Sci; 2004 May; 93(5):1185-94. PubMed ID: 15067695
[TBL] [Abstract][Full Text] [Related]
9. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.
Garrigues A; Escargueil AE; Orlowski S
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10347-52. PubMed ID: 12145328
[TBL] [Abstract][Full Text] [Related]
10. Activators of P-glycoprotein: Structure-activity relationships and investigation of their mode of action.
Sterz K; Möllmann L; Jacobs A; Baumert D; Wiese M
ChemMedChem; 2009 Nov; 4(11):1897-911. PubMed ID: 19777523
[TBL] [Abstract][Full Text] [Related]
11. Interaction of tomato lectin with ABC transporter in cancer cells: glycosylation confers functional conformation of P-gp.
Molnár J; Kars MD; Gündüz U; Engi H; Schumacher U; Van Damme EJ; Peumans WJ; Makovitzky J; Gyémánt N; Molnár P
Acta Histochem; 2009; 111(4):329-33. PubMed ID: 19124148
[TBL] [Abstract][Full Text] [Related]
12. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
13. P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
Acharya P; Tran TT; Polli JW; Ayrton A; Ellens H; Bentz J
Biochemistry; 2006 Dec; 45(51):15505-19. PubMed ID: 17176072
[TBL] [Abstract][Full Text] [Related]
14. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
15. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
16. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Arch Biochem Biophys; 2000 Nov; 383(1):91-8. PubMed ID: 11097180
[TBL] [Abstract][Full Text] [Related]
17. Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype.
Lima SA; Tavares J; Gameiro P; de Castro B; Cordeiro-da-Silva A
Eur J Pharmacol; 2008 Feb; 581(1-2):30-6. PubMed ID: 18190907
[TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells.
Aänismaa P; Seelig A
Biochemistry; 2007 Mar; 46(11):3394-404. PubMed ID: 17302433
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose.
Kitagawa S; Nabekura T; Nakamura Y; Takahashi T; Kashiwada Y
J Pharm Pharmacol; 2007 Jul; 59(7):965-9. PubMed ID: 17637191
[TBL] [Abstract][Full Text] [Related]
20. The translocation mechanism of P-glycoprotein.
Callaghan R; Ford RC; Kerr ID
FEBS Lett; 2006 Feb; 580(4):1056-63. PubMed ID: 16380120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
